PMID- 27566580 OWN - NLM STAT- MEDLINE DCOM- 20180315 LR - 20220318 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 7 IP - 39 DP - 2016 Sep 27 TI - HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis. PG - 63571-63582 LID - 10.18632/oncotarget.11541 [doi] AB - BACKGROUND: Trastuzumab-based therapy is a standard, targeted treatment for HER2-positive breast cancer in the adjuvant setting. However, patients do not benefit equally from it and the association between HER2 amplification level and patients' survival remains controversial. A systematic review and meta-analysis was conducted by incorporating all available evidence to evaluate the association between disease free survival (DFS) and HER2 amplification level. RESULTS: Three cohort studies involving 1360 HER2-positive breast cancer patients stratified by HER2 amplification magnitude were eligible for meta-analysis. The combined HRs for DFS were 1.05 (95% CI: 0.80-1.36, p = 0.74) and 0.97 (95% CI: 0.73-1.29, p = 0.83) for HER2 gene copy number (GCN) and HER2/CEP 17 ratio. No evidence of heterogeneity or public bias was found. METHODS: Databases including PubMed, Embase, Web of Science, and Cochrane Central Register of Controlled Trials (CENTRAL), were searched for eligible literature. HER2 amplification level was evaluated by fluorescence in situ hybridization (FISH) in terms of gene copy number (GCN) and HER2/CEP17 ratio. Hazard ratios (HRs) for DFS with 95% confidence interval (CI) according to the amplification level of HER2 were extracted. The outcomes were synthesized based on a fixed-effects model. CONCLUSIONS: HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based targeted therapy in the clinical adjuvant setting. FAU - Xu, Qian-Qian AU - Xu QQ AD - Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P. R. China. FAU - Pan, Bo AU - Pan B AD - Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P. R. China. FAU - Wang, Chang-Jun AU - Wang CJ AD - Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P. R. China. FAU - Zhou, Yi-Dong AU - Zhou YD AD - Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P. R. China. FAU - Mao, Feng AU - Mao F AD - Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P. R. China. FAU - Lin, Yan AU - Lin Y AD - Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P. R. China. FAU - Guan, Jing-Hong AU - Guan JH AD - Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P. R. China. FAU - Shen, Song-Jie AU - Shen SJ AD - Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P. R. China. FAU - Zhang, Xiao-Hui AU - Zhang XH AD - Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P. R. China. FAU - Xu, Ya-Li AU - Xu YL AD - Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P. R. China. FAU - Zhong, Ying AU - Zhong Y AD - Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P. R. China. FAU - Wang, Xue-Jing AU - Wang XJ AD - Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P. R. China. FAU - Zhang, Yan-Na AU - Zhang YN AD - Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P. R. China. FAU - Sun, Qiang AU - Sun Q AD - Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P. R. China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Review PT - Systematic Review PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Adjuvants, Immunologic) RN - 0 (Antineoplastic Agents, Immunological) RN - EC 2.7.10.1 (ERBB2 protein, human) RN - EC 2.7.10.1 (Receptor, ErbB-2) RN - P188ANX8CK (Trastuzumab) SB - IM MH - Adjuvants, Immunologic MH - Antineoplastic Agents, Immunological/*therapeutic use MH - Breast Neoplasms/genetics/metabolism/*pathology/therapy MH - Female MH - *Gene Amplification MH - Humans MH - Prognosis MH - Receptor, ErbB-2/*genetics/*metabolism MH - Trastuzumab/*therapeutic use PMC - PMC5325386 OTO - NOTNLM OT - HER2 amplification OT - HER2-positive breast cancer OT - adjuvant setting OT - prognosis OT - trastuzumab-based treatment COIS- CONFLICTS INTEREST There is no conflicts of interest of this study. EDAT- 2016/08/28 06:00 MHDA- 2018/03/16 06:00 PMCR- 2016/09/27 CRDT- 2016/08/28 06:00 PHST- 2016/06/21 00:00 [received] PHST- 2016/08/17 00:00 [accepted] PHST- 2016/08/28 06:00 [pubmed] PHST- 2018/03/16 06:00 [medline] PHST- 2016/08/28 06:00 [entrez] PHST- 2016/09/27 00:00 [pmc-release] AID - 11541 [pii] AID - 10.18632/oncotarget.11541 [doi] PST - ppublish SO - Oncotarget. 2016 Sep 27;7(39):63571-63582. doi: 10.18632/oncotarget.11541.